Maurizia Brunetto, MD

Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Pisa, Toscana, Italy

Disclosure(s): AbbVie: Advisor/Consultant, speaker bureau; EISAI-MSD: Advisor/Consultant, speaker bureau; Gilead Sciences, Inc.: Advisor/Consultant, speaker bureau; Janssen: Advisor/Consultant, speaker bureau; Roche: Advisor/Consultant, speaker bureau

Presentation(s):

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT